[ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia

Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychiatry research 1999-10, Vol.91 (3), p.163-173
Hauptverfasser: Verhoeff, Nicolaas Paul L.G, Soares, Jair C, D’Souza, Cyril D, Gil, Roberto, Degen, Kathleen, Abi-Dargham, Anissa, Zoghbi, Sami S, Fujita, Masahiro, Rajeevan, Nallakkandi, Seibyl, John P, Krystal, John H, van Dyck, Christopher H, Charney, Dennis S, Innis, Robert B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173
container_issue 3
container_start_page 163
container_title Psychiatry research
container_volume 91
creator Verhoeff, Nicolaas Paul L.G
Soares, Jair C
D’Souza, Cyril D
Gil, Roberto
Degen, Kathleen
Abi-Dargham, Anissa
Zoghbi, Sami S
Fujita, Masahiro
Rajeevan, Nallakkandi
Seibyl, John P
Krystal, John H
van Dyck, Christopher H
Charney, Dennis S
Innis, Robert B
description Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possible changes of the regional GABA A-benzodiazepine receptor distribution volume (BZR V 3-p) in schizophrenia in vivo, using a larger sample size than previous studies. Single photon emission computed tomography (SPECT) with [ 123I]iomazenil was used with a constant infusion paradigm to measure the BZR V 3-p under sustained radiotracer equilibrium conditions. Twenty-five patients with schizophrenia and 24 matched healthy control subjects were studied. Positive and Negative Syndrome Scale (PANSS) ratings were done in all subjects. Statistical parametric mapping (SPM) 96 was used to compare patients and control subjects as well as to study the relationship between SPECT results and composite PANSS scores based on two factorial models: the pentagonal model (positive, negative, dysphoric mood, activation, and autistic preoccupation factors) and the taxometric model (disorganized dimension). On the basis of ‘absolute’ values of V 3-p with no normalization for total brain uptake, the schizophrenic patients showed no signficant differences in BZR levels compared to the healthy control subjects. With a global normalization procedure, which is more sensitive to relative regional differences in activity, BZR V 3-p was significantly decreased in the patients in the left precentral gyrus (BA 6). The relative BZR V 3-p showed a significant positive correlation with duration of illness in the superior occipital gyri (BA 19). No significant correlations were observed between either absolute or relative BZR V 3-p and either age or any of the composite PANSS scores based on any of the two factorial models in either patients or control subjects. No significant differences were observed between cigarette smoking vs. non-smoking patients, nor between the patients on atypical antipsychotics vs. on typical antipsychotics vs. not on any antipsychotics. In general, no significant differences in BZR V 3-p were observed between patients and control subjects, except for a decrease in relative BZR V 3-p in the left precentral gyrus. Grey matter atrophy is unlikely to be the cause for this decrease. However, we could not exclude that possibility. The positive correlation with duration of illn
doi_str_mv 10.1016/S0925-4927(99)00027-X
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69416145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092549279900027X</els_id><sourcerecordid>69416145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-e98a893772280b47d43a0fed30f000eaaa315cbf401422523f7c5885302106ab3</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoOl4eQelKdFHNtU1WIsOoA4LCKAgiIU1PNdJpa9IRnKc3MxVx5-rA4fvP5UPokOAzgkl2PsOKipQrmp8odYoxpnn6tIFGROY0zQXONtHoF9lBuyG8R4bJjG2jHYIzToTEI3T9nBDKpi_Tdm6W0Lg6md1Pxg9JAc2yLV3sda6BxIOFrm994ubm1TWviWuSYN_csu3efIyZfbRVmTrAwU_dQ49Xk4fxTXp7dz0dX96mlmPZp6CkkYrlOaUSFzwvOTO4gpLhKr4AxhhGhC0qjgmnVFBW5VZIKRim8WZTsD10PMztfPuxgNDruQsW6to00C6CzhQnGeEigmIArW9D8FDpzsfj_ZcmWK8M6rVBvdKjldJrg_op5o5-FiyKOZR_UoOyCFwMAMQ3Px14HayDxkLpoqVel637Z8U3wYB_CA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69416145</pqid></control><display><type>article</type><title>[ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Verhoeff, Nicolaas Paul L.G ; Soares, Jair C ; D’Souza, Cyril D ; Gil, Roberto ; Degen, Kathleen ; Abi-Dargham, Anissa ; Zoghbi, Sami S ; Fujita, Masahiro ; Rajeevan, Nallakkandi ; Seibyl, John P ; Krystal, John H ; van Dyck, Christopher H ; Charney, Dennis S ; Innis, Robert B</creator><creatorcontrib>Verhoeff, Nicolaas Paul L.G ; Soares, Jair C ; D’Souza, Cyril D ; Gil, Roberto ; Degen, Kathleen ; Abi-Dargham, Anissa ; Zoghbi, Sami S ; Fujita, Masahiro ; Rajeevan, Nallakkandi ; Seibyl, John P ; Krystal, John H ; van Dyck, Christopher H ; Charney, Dennis S ; Innis, Robert B</creatorcontrib><description>Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possible changes of the regional GABA A-benzodiazepine receptor distribution volume (BZR V 3-p) in schizophrenia in vivo, using a larger sample size than previous studies. Single photon emission computed tomography (SPECT) with [ 123I]iomazenil was used with a constant infusion paradigm to measure the BZR V 3-p under sustained radiotracer equilibrium conditions. Twenty-five patients with schizophrenia and 24 matched healthy control subjects were studied. Positive and Negative Syndrome Scale (PANSS) ratings were done in all subjects. Statistical parametric mapping (SPM) 96 was used to compare patients and control subjects as well as to study the relationship between SPECT results and composite PANSS scores based on two factorial models: the pentagonal model (positive, negative, dysphoric mood, activation, and autistic preoccupation factors) and the taxometric model (disorganized dimension). On the basis of ‘absolute’ values of V 3-p with no normalization for total brain uptake, the schizophrenic patients showed no signficant differences in BZR levels compared to the healthy control subjects. With a global normalization procedure, which is more sensitive to relative regional differences in activity, BZR V 3-p was significantly decreased in the patients in the left precentral gyrus (BA 6). The relative BZR V 3-p showed a significant positive correlation with duration of illness in the superior occipital gyri (BA 19). No significant correlations were observed between either absolute or relative BZR V 3-p and either age or any of the composite PANSS scores based on any of the two factorial models in either patients or control subjects. No significant differences were observed between cigarette smoking vs. non-smoking patients, nor between the patients on atypical antipsychotics vs. on typical antipsychotics vs. not on any antipsychotics. In general, no significant differences in BZR V 3-p were observed between patients and control subjects, except for a decrease in relative BZR V 3-p in the left precentral gyrus. Grey matter atrophy is unlikely to be the cause for this decrease. However, we could not exclude that possibility. The positive correlation with duration of illness might reflect the relative preservation of neurons expressing BZR in the superior occipital gyri as compared to other cortical brain regions in schizophrenia.</description><identifier>ISSN: 0925-4927</identifier><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7506</identifier><identifier>DOI: 10.1016/S0925-4927(99)00027-X</identifier><identifier>PMID: 10641580</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Brain - diagnostic imaging ; Brain - physiopathology ; Brain Mapping ; Cerebral Cortex - diagnostic imaging ; Cerebral Cortex - physiopathology ; Dominance, Cerebral - physiology ; Female ; Flumazenil - analogs &amp; derivatives ; Frontal Lobe - diagnostic imaging ; Frontal Lobe - physiopathology ; GABA ; Humans ; Iodine Radioisotopes ; Male ; Middle Aged ; Negative symptoms ; Positive symptoms ; Psychiatric Status Rating Scales ; Psychosis ; Receptors, GABA-A - physiology ; Schizophrenia - diagnostic imaging ; Schizophrenia - physiopathology ; Thought disorganization ; Tomography, Emission-Computed, Single-Photon</subject><ispartof>Psychiatry research, 1999-10, Vol.91 (3), p.163-173</ispartof><rights>1999 Elsevier Science Ireland Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-e98a893772280b47d43a0fed30f000eaaa315cbf401422523f7c5885302106ab3</citedby><cites>FETCH-LOGICAL-c408t-e98a893772280b47d43a0fed30f000eaaa315cbf401422523f7c5885302106ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0925-4927(99)00027-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10641580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verhoeff, Nicolaas Paul L.G</creatorcontrib><creatorcontrib>Soares, Jair C</creatorcontrib><creatorcontrib>D’Souza, Cyril D</creatorcontrib><creatorcontrib>Gil, Roberto</creatorcontrib><creatorcontrib>Degen, Kathleen</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><creatorcontrib>Zoghbi, Sami S</creatorcontrib><creatorcontrib>Fujita, Masahiro</creatorcontrib><creatorcontrib>Rajeevan, Nallakkandi</creatorcontrib><creatorcontrib>Seibyl, John P</creatorcontrib><creatorcontrib>Krystal, John H</creatorcontrib><creatorcontrib>van Dyck, Christopher H</creatorcontrib><creatorcontrib>Charney, Dennis S</creatorcontrib><creatorcontrib>Innis, Robert B</creatorcontrib><title>[ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possible changes of the regional GABA A-benzodiazepine receptor distribution volume (BZR V 3-p) in schizophrenia in vivo, using a larger sample size than previous studies. Single photon emission computed tomography (SPECT) with [ 123I]iomazenil was used with a constant infusion paradigm to measure the BZR V 3-p under sustained radiotracer equilibrium conditions. Twenty-five patients with schizophrenia and 24 matched healthy control subjects were studied. Positive and Negative Syndrome Scale (PANSS) ratings were done in all subjects. Statistical parametric mapping (SPM) 96 was used to compare patients and control subjects as well as to study the relationship between SPECT results and composite PANSS scores based on two factorial models: the pentagonal model (positive, negative, dysphoric mood, activation, and autistic preoccupation factors) and the taxometric model (disorganized dimension). On the basis of ‘absolute’ values of V 3-p with no normalization for total brain uptake, the schizophrenic patients showed no signficant differences in BZR levels compared to the healthy control subjects. With a global normalization procedure, which is more sensitive to relative regional differences in activity, BZR V 3-p was significantly decreased in the patients in the left precentral gyrus (BA 6). The relative BZR V 3-p showed a significant positive correlation with duration of illness in the superior occipital gyri (BA 19). No significant correlations were observed between either absolute or relative BZR V 3-p and either age or any of the composite PANSS scores based on any of the two factorial models in either patients or control subjects. No significant differences were observed between cigarette smoking vs. non-smoking patients, nor between the patients on atypical antipsychotics vs. on typical antipsychotics vs. not on any antipsychotics. In general, no significant differences in BZR V 3-p were observed between patients and control subjects, except for a decrease in relative BZR V 3-p in the left precentral gyrus. Grey matter atrophy is unlikely to be the cause for this decrease. However, we could not exclude that possibility. The positive correlation with duration of illness might reflect the relative preservation of neurons expressing BZR in the superior occipital gyri as compared to other cortical brain regions in schizophrenia.</description><subject>Adult</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - physiopathology</subject><subject>Brain Mapping</subject><subject>Cerebral Cortex - diagnostic imaging</subject><subject>Cerebral Cortex - physiopathology</subject><subject>Dominance, Cerebral - physiology</subject><subject>Female</subject><subject>Flumazenil - analogs &amp; derivatives</subject><subject>Frontal Lobe - diagnostic imaging</subject><subject>Frontal Lobe - physiopathology</subject><subject>GABA</subject><subject>Humans</subject><subject>Iodine Radioisotopes</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Negative symptoms</subject><subject>Positive symptoms</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychosis</subject><subject>Receptors, GABA-A - physiology</subject><subject>Schizophrenia - diagnostic imaging</subject><subject>Schizophrenia - physiopathology</subject><subject>Thought disorganization</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><issn>0925-4927</issn><issn>0165-1781</issn><issn>1872-7506</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKxDAUhoMoOl4eQelKdFHNtU1WIsOoA4LCKAgiIU1PNdJpa9IRnKc3MxVx5-rA4fvP5UPokOAzgkl2PsOKipQrmp8odYoxpnn6tIFGROY0zQXONtHoF9lBuyG8R4bJjG2jHYIzToTEI3T9nBDKpi_Tdm6W0Lg6md1Pxg9JAc2yLV3sda6BxIOFrm994ubm1TWviWuSYN_csu3efIyZfbRVmTrAwU_dQ49Xk4fxTXp7dz0dX96mlmPZp6CkkYrlOaUSFzwvOTO4gpLhKr4AxhhGhC0qjgmnVFBW5VZIKRim8WZTsD10PMztfPuxgNDruQsW6to00C6CzhQnGeEigmIArW9D8FDpzsfj_ZcmWK8M6rVBvdKjldJrg_op5o5-FiyKOZR_UoOyCFwMAMQ3Px14HayDxkLpoqVel637Z8U3wYB_CA</recordid><startdate>19991011</startdate><enddate>19991011</enddate><creator>Verhoeff, Nicolaas Paul L.G</creator><creator>Soares, Jair C</creator><creator>D’Souza, Cyril D</creator><creator>Gil, Roberto</creator><creator>Degen, Kathleen</creator><creator>Abi-Dargham, Anissa</creator><creator>Zoghbi, Sami S</creator><creator>Fujita, Masahiro</creator><creator>Rajeevan, Nallakkandi</creator><creator>Seibyl, John P</creator><creator>Krystal, John H</creator><creator>van Dyck, Christopher H</creator><creator>Charney, Dennis S</creator><creator>Innis, Robert B</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991011</creationdate><title>[ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia</title><author>Verhoeff, Nicolaas Paul L.G ; Soares, Jair C ; D’Souza, Cyril D ; Gil, Roberto ; Degen, Kathleen ; Abi-Dargham, Anissa ; Zoghbi, Sami S ; Fujita, Masahiro ; Rajeevan, Nallakkandi ; Seibyl, John P ; Krystal, John H ; van Dyck, Christopher H ; Charney, Dennis S ; Innis, Robert B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-e98a893772280b47d43a0fed30f000eaaa315cbf401422523f7c5885302106ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - physiopathology</topic><topic>Brain Mapping</topic><topic>Cerebral Cortex - diagnostic imaging</topic><topic>Cerebral Cortex - physiopathology</topic><topic>Dominance, Cerebral - physiology</topic><topic>Female</topic><topic>Flumazenil - analogs &amp; derivatives</topic><topic>Frontal Lobe - diagnostic imaging</topic><topic>Frontal Lobe - physiopathology</topic><topic>GABA</topic><topic>Humans</topic><topic>Iodine Radioisotopes</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Negative symptoms</topic><topic>Positive symptoms</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychosis</topic><topic>Receptors, GABA-A - physiology</topic><topic>Schizophrenia - diagnostic imaging</topic><topic>Schizophrenia - physiopathology</topic><topic>Thought disorganization</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verhoeff, Nicolaas Paul L.G</creatorcontrib><creatorcontrib>Soares, Jair C</creatorcontrib><creatorcontrib>D’Souza, Cyril D</creatorcontrib><creatorcontrib>Gil, Roberto</creatorcontrib><creatorcontrib>Degen, Kathleen</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><creatorcontrib>Zoghbi, Sami S</creatorcontrib><creatorcontrib>Fujita, Masahiro</creatorcontrib><creatorcontrib>Rajeevan, Nallakkandi</creatorcontrib><creatorcontrib>Seibyl, John P</creatorcontrib><creatorcontrib>Krystal, John H</creatorcontrib><creatorcontrib>van Dyck, Christopher H</creatorcontrib><creatorcontrib>Charney, Dennis S</creatorcontrib><creatorcontrib>Innis, Robert B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verhoeff, Nicolaas Paul L.G</au><au>Soares, Jair C</au><au>D’Souza, Cyril D</au><au>Gil, Roberto</au><au>Degen, Kathleen</au><au>Abi-Dargham, Anissa</au><au>Zoghbi, Sami S</au><au>Fujita, Masahiro</au><au>Rajeevan, Nallakkandi</au><au>Seibyl, John P</au><au>Krystal, John H</au><au>van Dyck, Christopher H</au><au>Charney, Dennis S</au><au>Innis, Robert B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>1999-10-11</date><risdate>1999</risdate><volume>91</volume><issue>3</issue><spage>163</spage><epage>173</epage><pages>163-173</pages><issn>0925-4927</issn><issn>0165-1781</issn><eissn>1872-7506</eissn><abstract>Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possible changes of the regional GABA A-benzodiazepine receptor distribution volume (BZR V 3-p) in schizophrenia in vivo, using a larger sample size than previous studies. Single photon emission computed tomography (SPECT) with [ 123I]iomazenil was used with a constant infusion paradigm to measure the BZR V 3-p under sustained radiotracer equilibrium conditions. Twenty-five patients with schizophrenia and 24 matched healthy control subjects were studied. Positive and Negative Syndrome Scale (PANSS) ratings were done in all subjects. Statistical parametric mapping (SPM) 96 was used to compare patients and control subjects as well as to study the relationship between SPECT results and composite PANSS scores based on two factorial models: the pentagonal model (positive, negative, dysphoric mood, activation, and autistic preoccupation factors) and the taxometric model (disorganized dimension). On the basis of ‘absolute’ values of V 3-p with no normalization for total brain uptake, the schizophrenic patients showed no signficant differences in BZR levels compared to the healthy control subjects. With a global normalization procedure, which is more sensitive to relative regional differences in activity, BZR V 3-p was significantly decreased in the patients in the left precentral gyrus (BA 6). The relative BZR V 3-p showed a significant positive correlation with duration of illness in the superior occipital gyri (BA 19). No significant correlations were observed between either absolute or relative BZR V 3-p and either age or any of the composite PANSS scores based on any of the two factorial models in either patients or control subjects. No significant differences were observed between cigarette smoking vs. non-smoking patients, nor between the patients on atypical antipsychotics vs. on typical antipsychotics vs. not on any antipsychotics. In general, no significant differences in BZR V 3-p were observed between patients and control subjects, except for a decrease in relative BZR V 3-p in the left precentral gyrus. Grey matter atrophy is unlikely to be the cause for this decrease. However, we could not exclude that possibility. The positive correlation with duration of illness might reflect the relative preservation of neurons expressing BZR in the superior occipital gyri as compared to other cortical brain regions in schizophrenia.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>10641580</pmid><doi>10.1016/S0925-4927(99)00027-X</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0925-4927
ispartof Psychiatry research, 1999-10, Vol.91 (3), p.163-173
issn 0925-4927
0165-1781
1872-7506
language eng
recordid cdi_proquest_miscellaneous_69416145
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Brain - diagnostic imaging
Brain - physiopathology
Brain Mapping
Cerebral Cortex - diagnostic imaging
Cerebral Cortex - physiopathology
Dominance, Cerebral - physiology
Female
Flumazenil - analogs & derivatives
Frontal Lobe - diagnostic imaging
Frontal Lobe - physiopathology
GABA
Humans
Iodine Radioisotopes
Male
Middle Aged
Negative symptoms
Positive symptoms
Psychiatric Status Rating Scales
Psychosis
Receptors, GABA-A - physiology
Schizophrenia - diagnostic imaging
Schizophrenia - physiopathology
Thought disorganization
Tomography, Emission-Computed, Single-Photon
title [ 123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A06%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B%20123I%5DIomazenil%20SPECT%20benzodiazepine%20receptor%20imaging%20in%20schizophrenia&rft.jtitle=Psychiatry%20research&rft.au=Verhoeff,%20Nicolaas%20Paul%20L.G&rft.date=1999-10-11&rft.volume=91&rft.issue=3&rft.spage=163&rft.epage=173&rft.pages=163-173&rft.issn=0925-4927&rft.eissn=1872-7506&rft_id=info:doi/10.1016/S0925-4927(99)00027-X&rft_dat=%3Cproquest_cross%3E69416145%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69416145&rft_id=info:pmid/10641580&rft_els_id=S092549279900027X&rfr_iscdi=true